Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12281)	11/20/1999 10:19:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

So to clear things up is this right? In regard to Hemo trauma>>>>>>>>>>>"Phase III data under analysis(decrease in placebo event rate>50% from phase II) This is NEW and IMPORTANT. Slides reference P II, placebo, event rate at 32% meaning P III placebo event rate was below 16%<<<<<<< AND IN REGARD TO MENINGO>>>>>>>>>>>>>>>Clinical benefit in reduction of mortality and morbidities (e.g. severe amputations) confirmed. What is new about that?? The (severe amputations) part. IMO means the less severe amputations were not that different in either of the stratified arms. Also demonstrates another reason why analysis was probably complex. If more fingers and toes lost in treatment group what does this mean compared to fewer more sever amputations? Just trying to illustrate that severity of amputations in itself presents a statistical situation that requires analysis. Scannon slides say BLA and MMA in progress. Help! What's a MMA???<<<<<<<<<<<<<<<<<<,